Market closed
DexCom/DXCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
DXCM
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
9,550
Website
DexCom Metrics
BasicAdvanced
$28B
Market cap
42.83
P/E ratio
$1.62
EPS
1.16
Beta
-
Dividend rate
Price and volume
Market cap
$28B
Beta
1.16
52-week high
$142.00
52-week low
$62.34
Average daily volume
4.1M
Financial strength
Current ratio
2.815
Quick ratio
2.392
Long term debt to equity
105.685
Total debt to equity
106.573
Interest coverage (TTM)
35.49%
Management effectiveness
Return on assets (TTM)
6.25%
Return on equity (TTM)
29.41%
Valuation
Price to earnings (TTM)
42.826
Price to revenue (TTM)
6.861
Price to book
11.39
Price to tangible book (TTM)
12.08
Price to free cash flow (TTM)
40.564
Growth
Revenue change (TTM)
23.05%
Earnings per share change (TTM)
86.93%
3-year revenue growth (CAGR)
21.94%
3-year earnings per share growth (CAGR)
5.45%
What the Analysts think about DexCom
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
DexCom Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DexCom Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DexCom News
AllArticlesVideos
DXCM INVESTOR ALERT: Lose Money on Your DexCom, Inc. Investment? Contact BFA Law by October 21 Deadline about Securities Fraud Class Action
Accesswire·17 hours ago
Shareholders That Lost Money on DexCom, Inc. (DXCM) Should Contact Levi & Korsinsky About Pending Class Action - DXCM
Accesswire·20 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM
Accesswire·20 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $28B as of October 12, 2024.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 42.83 as of October 12, 2024.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of October 12, 2024.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.